BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M